SRRK ▼ -0.6% - Scholar Rock Holding Corporation $SRRK Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) Scholar Rock shares fell 0.6% today despite the company announcing FDA approval of ISEMBYLD (apitegromab-mstn), marking the first muscle-targeted treatment for spinal muscular atrophy in both children and adults. The modest decline suggests investors may have already priced in the approval ahead of today's announcement, or are taking a cautious view on the commercial prospects for the newly approved therapy. 11-SEP-2026 06:26 PM ET